Zetia Antitrust Litigation
Berger Montague represents a proposed class of direct purchasers of the drug Zetia (ezetimibe).
Plaintiffs allege that Merck & Co. Inc., Merck Sharp & Dohme Corp., Schering-Plough Corp., Schering Corp., MSP Singapore Co. LLC (collectively, “Merck”), Glenmark Pharmaceuticals LTD, and Glenmark Generics Inc. (together, “Glenmark”) entered into a reverse payment agreement that delayed generic competition to Merck’s brand cholesterol drug Zetia. The complaint alleges that this anticompetitive agreement caused plaintiffs to pay hundreds of millions in overcharges.
Motion to dismiss briefing is underway and a motion to consolidate is also pending before the U.S. Judicial Panel on Multidistrict Litigation.
LEAD ATTORNEY: David F. Sorensen